ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Ventyx Biosciences, Inc. | VTYX | United States of America | $1.00B | 524 |
| Compass Therapeutics, Inc. | CMPX | United States of America | $370.98M | 382 |
| Inhibrx Biosciences, Inc. | INBX | United States of America | $1.36B | 160 |
| CytomX Therapeutics, Inc. | CTMX | United States of America | $977.12M | 846 |
| Gubra A/S | GUBRA | Denmark | $869.63M | 154 |
| Janux Therapeutics, Inc. | JANX | United States of America | $906.23M | 437 |
| BioAge Labs, Inc. | BIOA | United States of America | $1.08B | 171 |
| Xencor Inc | XNCR | United States of America | $890.44M | 926 |
| Vor Biopharma Inc. | VOR | United States of America | $881.70M | 474 |
| SELLAS Life Sciences Group, Inc. | SLS | United States of America | $2.51B | 1,254 |
| Arbutus Biopharma Corp | ABUS | United States of America | $962.01M | 1,062 |
| OMEROS CORP | OMER | United States of America | $744.02M | 824 |
| Sana Biotechnology, Inc. | SANA | United States of America | $853.97M | 444 |
| GH Research PLC | GHRS | Ireland | $846.70M | 197 |
| Bicara Therapeutics Inc. | BCAX | United States of America | $844.74M | 269 |
| Annexon, Inc. | ANNX | United States of America | $833.22M | 555 |
| Design Therapeutics, Inc. | DSGN | United States of America | $665.17M | 285 |
| Jade Biosciences, Inc. | JBIO | United States of America | $1.33B | 518 |
| Solid Biosciences Inc. | SLDB | United States of America | $1.03B | 756 |
| RELMADA THERAPEUTICS, INC. | RLMD | United States of America | $683.47M | 639 |
| Alto Neuroscience, Inc. | ANRO | United States of America | $915.60M | 216 |
| ARVINAS, INC. | ARVN | United States of America | $518.11M | 644 |
| Kura Oncology, Inc. | KURA | United States of America | $718.12M | 820 |
| COMPASS Pathways plc | CMPS | United Kingdom | $1.84B | 399 |
| Cullinan Therapeutics, Inc. | CGEM | United States of America | $706.55M | 508 |
| Bright Minds Biosciences Inc. | DRUG | Canada | $699.39M | 463 |
| LB PHARMACEUTICALS INC | LBRX | United States of America | $803.81M | 143 |
| BridgeBio Oncology Therapeutics, Inc. | BBOT | United States of America | $664.09M | 190 |
| GYRE THERAPEUTICS, INC. | GYRE | United States of America | $671.44M | 1,607 |
| Alpha Tau Medical Ltd. | DRTS | United States of America | $844.10M | 267 |
| Replimune Group, Inc. | REPL | United States of America | $841.41M | 681 |
| Prime Medicine, Inc. | PRME | United States of America | $552.69M | 312 |
| MeiraGTx Holdings plc | MGTX | Cayman Islands | $618.14M | 520 |
| Allogene Therapeutics, Inc. | ALLO | United States of America | $742.08M | 644 |
| Ocugen, Inc. | OCGN | United States of America | $507.78M | 935 |
| Inventiva S.A. | IVA | United States of America | $557.31M | 226 |
| PROKIDNEY CORP. | PROK | United States of America | $522.56M | 421 |
| Tectonic Therapeutic, Inc. | TECX | United States of America | $647.97M | 592 |
| PROTHENA CORP PUBLIC LTD CO | PRTA | United States of America | $443.43M | 1,039 |
| Zura Bio Ltd | ZURA | Cayman Islands | $538.92M | 444 |
| NovaBridge Biosciences | NBP | Cayman Islands | $533.68M | 356 |
| Upstream Bio, Inc. | UPB | United States of America | $383.66M | 152 |
| Opthea Ltd | OPT | Australia | $524.82M | 1,421 |
| Shattuck Labs, Inc. | STTK | United States of America | $314.77M | 436 |
| LUMOSA THERAPEUTICS CO., LTD. | 6535 | Taiwan | $503.97M | 1,355 |
| Entrada Therapeutics, Inc. | TRDA | United States of America | $299.70M | 489 |
| Invivyd, Inc. | IVVD | United States of America | $482.20M | 489 |
| Contineum Therapeutics, Inc. | CTNM | United States of America | $546.96M | 202 |
| 4D Molecular Therapeutics, Inc. | FDMT | United States of America | $475.29M | 487 |
| Zentalis Pharmaceuticals, Inc. | ZNTL | United States of America | $284.75M | 587 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.